Terns Pharmaceuticals Inc (NAS:TERN)
$ 6.15 0.27 (4.59%) Market Cap: 397.76 Mil Enterprise Value: 140.07 Mil PE Ratio: 0 PB Ratio: 1.68 GF Score: 34/100

Terns Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2024 / 09:30PM GMT
Release Date Price: $6.13 (-9.19%)
Eric Joseph JPMorgan;Analyst

Good afternoon. I'm Eric Joseph, senior biotech analyst with JPMorgan. And our next presenting company is Terns Pharmaceuticals. Presenting on behalf of the company is President and Head of R&D, Erin Quirk.

(Conference Instructions) So with that, Erin, thanks for joining us.

Erin Quirk Terns Pharmaceuticals
Inc. - President & Head of Research & Development

Great. Eric, thanks so much for the introduction. And thanks to you and the entire JPMorgan team for the opportunity to be at the conference and present today. It's always great to be at JPMorgan, and we really appreciate the support and invitation.

So I'll give you an overview of Terns today and the really exciting outlook we have for 2024. As always, I'd invite you to go to our website to look at disclaimers regarding forward-looking statements.

So Terns is a biotech company. We're developing small molecule medicines with clinically validated mechanisms of action to address important needs focused currently on oncology and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot